Since there is no abstract available we provide the first paragraph.
Over the past decade, neoadjuvant chemoradiotherapy has established as the standard approach for selected patients with advanced non-metastatic rectal cancer. But now meta-analyses, analysing data from more recent phase 3 randomized controlled trials raise a series of question and uncertainty about benefit-risk analysis neoadjuvant treatment. Given that this information is important not only for surgeons and oncologists but also patients, we describe benefits and complications of neoadjuvant treatment in a lack of robust biomarkers to predict who patients really respond and benefit from the preoperative chemoradiotherapy.

(Citation: Gastric & Breast Cancer 2012; 11(3): 154-156).

Back

Full Text

PDF Version